Imunon IDMC backs continued Phase 2 IMNN-001 MRD study after safety review - IMNN News | RalliesImunon IDMC backs continued Phase 2 IMNN-001 MRD study after safety review
I
IMNN• IDMC review supports continued Phase 2 testing
- Imunon’s independent monitoring committee backed continued Phase 2 testing of IMNN-001 in an ovarian cancer MRD study with no changes.
- Safety review found no new signals, supporting the program’s differentiated tolerability profile across combination and maintenance use.
- Preliminary Phase 2 MRD results were presented in July, pointing to deeper anti-tumor activity and immune activation versus control.
- Clean safety read-through also supported ongoing execution of the pivotal Phase 3 OVATION 3 trial.
ZEO
•
